UroGen Pharma Ltd.

Good morning, ladies and gentlemen. Thank you for standing by and welcome to EuroGen Pharma's third quarter 2022 financial results and business update conference call. It is now my pleasure to turn the call over to Vincent Perrone, Senior Director of Investor Relations for EuroGen Pharma. Please go ahead.

Thank you, operator.

Good morning, everyone, and welcome to EuroGen Pharma's third quarter 2022 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter-ended September 30th, 2022. The press release can be accessed on the investors portion of our website at investors.eurogen.com. Joining me on the call today are Liz Barrett, President and Chief Executive Officer, Dr. Mark Schoenberg, Chief Medical Officer, Jeff Bova, Chief Commercial Officer, and Don Kim, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities relating to gel mito, the expected benefits of the FDA's expansion of the in-use period for gel mito, our ongoing and planned clinical trials, commercial and clinical milestones in the year ahead, the growth potential for gel mito, the design potential benefits, and commercial potential for UGN-102 if approved, the design, potential benefits, and commercial potential of UGN 301, potential future commercialization activities for UGN 102 if approved, data presentations, expected regulatory filings and timing thereof, future research and development efforts, and our financial and other corporate goals, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents including under the risk factors heading of our quarterly report on Form 10-Q for the quarter ended September 30th, 2022, filed today. There are caution not to place undue reliance on these forward-looking statements, and your agenda claims any obligation to update these statements. I will now turn the call over to Liz. Liz?